Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable Recurrent Hepatocellular CarcinomaPhase II Non-randomized Control Clinical Trial

Next Previous
X
Search
Trial Profile

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable Recurrent Hepatocellular CarcinomaPhase II Non-randomized Control Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Lenvatinib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms TALENT

    • Most Recent Events

    • 20 Jan 2024 Results ( Until Sep 30th, 2023, n=14) assessing safety and efficacy of Neo-adjuvant tislelizumab combined with lenvatinib treatment for resectable, recurrent hepatocellular carcinoma presented at the 2024 Gastrointestinal Cancers Symposium
    • 13 Sep 2022 Results(n=11, of Arm 1: neoadjuvant tislelizumab ) assessing the efficacy and safety of neoadjuvant tislelizumab inresectable recurrent hepatocellular carcinoma patientspresented at the 47th European Society for Medical Oncology Congress
    • 31 Mar 2022 Planned End Date changed from 1 Jun 2023 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top